EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib

Ashley Jones, Samuele Bonomi iD, Keith E Stockerl-Goldstein, Randall J Bateman

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70296 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Ashley Jones und 3 weiteren Autor:innen. Beteiligte Einrichtung: Saint Louis University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Imatinib Mesylate, Dementia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tracy Family Foundation, Foundation for Barnes-Jewish Hospital, Payne Family.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a patient on imatinib who developed progressive cognitive, mood, and behavioral alterations. He was investigated for dementia and psychiatric disorders but ultimately improved only after discontinuing imatinib. His decompensation years after therapy start, followed by complete and rapid remission, is atypical. We also review the most recent neurobiological findings on the role of tyrosine kinase alterations in dementia and their importance for mood regulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateDementiaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAntineoplastic AgentsProtein Kinase InhibitorsHumansMaleDiagnosis, DifferentialAged

Stichwörter der Autor:innen

behavioral neurologychronic myeloid leukemiadementianeuropsychiatrytyrosin kinase inhibitors

Substanzen

Imatinib MesylateAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Saint Louis University School of Medicine, St. Louis, Missouri, USA.
  • Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
  • Knight Alzheimer Disease Research Center, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.

ORCID-Profile: Samuele Bonomi

Förderung

  • Tracy Family Foundation
  • Foundation for Barnes-Jewish Hospital
  • Payne Family
  • JTL Family Fund
  • Community Foundation for the Land of Lincoln
  • Mary & Jay Sullivan
  • Richard Frimel & Gary Werths
  • GHR Foundation

Zitieren

APA

Jones, A., Bonomi, S., Stockerl-Goldstein, K. E., & Bateman, R. J. (2025). Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70296

Vancouver

Jones A, Bonomi S, Stockerl-Goldstein KE, Bateman RJ. Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70296

BibTeX
@article{Jones2025,
  author = {Jones, Ashley and Bonomi, Samuele and Stockerl-Goldstein, Keith E and Bateman, Randall J},
  title = {Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70296}
}
Kostenlos starten →